Does the media refer more to AARD or KYNB?

In the previous week, Aardvark Therapeutics and Aardvark Therapeutics both had 1 articles in the media. Aardvark Therapeutics' average media sentiment score of 0.59 beat Kyntra Bio's score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aardvark Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CUE or KYNB?

Kyntra Bio has a consensus price target of $30.00, indicating a potential upside of 293.18%. Given Kyntra Bio's stronger consensus rating and higher probable upside, analysts plainly believe Kyntra Bio is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kyntra Bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is CUE or KYNB more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to Cue Biopharma's net margin of -59.65%. Kyntra Bio's return on equity of 0.00% beat Cue Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Cue Biopharma -59.65% -98.30% -53.69% Kyntra Bio 2,199.13% N/A -36.71%

Kyntra Bio (KYNB) Competitors

$7.63 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$7.65 +0.02 (+0.21%)

As of 07/2/2026 05:29 PM Eastern

Compare

KYNB vs. FTLF, AARD, ONCY, ALDX, and CUE

Should you buy Kyntra Bio stock or one of its competitors? MarketBeat compares Kyntra Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kyntra Bio include FitLife Brands (FTLF), Aardvark Therapeutics (AARD), Oncolytics Biotech (ONCY), Aldeyra Therapeutics (ALDX), and Cue Biopharma (CUE). These companies are all part of the "pharmaceutical products" industry.

How does Kyntra Bio compare to FitLife Brands?

FitLife Brands (NASDAQ:FTLF) and Kyntra Bio (NASDAQ:KYNB) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Kyntra Bio has a net margin of 2,199.13% compared to FitLife Brands' net margin of 6.64%. FitLife Brands' return on equity of 18.31% beat Kyntra Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
FitLife Brands	6.64%	18.31%	8.21%
Kyntra Bio	2,199.13%	N/A	-36.71%

FitLife Brands presently has a consensus price target of $21.50, indicating a potential upside of 86.96%. Kyntra Bio has a consensus price target of $30.00, indicating a potential upside of 293.18%. Given Kyntra Bio's stronger consensus rating and higher probable upside, analysts clearly believe Kyntra Bio is more favorable than FitLife Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Kyntra Bio had 1 more articles in the media than FitLife Brands. MarketBeat recorded 1 mentions for Kyntra Bio and 0 mentions for FitLife Brands. FitLife Brands' average media sentiment score of 0.00 equaled Kyntra Bio'saverage media sentiment score.

Company	Overall Sentiment
FitLife Brands	Neutral
Kyntra Bio	Neutral

Kyntra Bio has lower revenue, but higher earnings than FitLife Brands. Kyntra Bio is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FitLife Brands	$81.46M	1.33	$6.33M	$0.60	19.17
Kyntra Bio	$6.44M	4.80	$183.45M	$40.46	0.19

FitLife Brands has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market. Comparatively, Kyntra Bio has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

2.3% of FitLife Brands shares are owned by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are owned by institutional investors. 61.7% of FitLife Brands shares are owned by insiders. Comparatively, 4.2% of Kyntra Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Kyntra Bio beats FitLife Brands on 10 of the 16 factors compared between the two stocks.

How does Kyntra Bio compare to Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and Kyntra Bio (NASDAQ:KYNB) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

72.7% of Kyntra Bio shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Kyntra Bio has higher revenue and earnings than Aardvark Therapeutics. Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Kyntra Bio	$6.44M	4.80	$183.45M	$40.46	0.19

In the previous week, Aardvark Therapeutics and Aardvark Therapeutics both had 1 articles in the media. Aardvark Therapeutics' average media sentiment score of 0.59 beat Kyntra Bio's score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aardvark Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aardvark Therapeutics has a beta of 3.93, indicating that its share price is 293% more volatile than the broader market. Comparatively, Kyntra Bio has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

Aardvark Therapeutics presently has a consensus target price of $19.70, indicating a potential upside of 245.61%. Kyntra Bio has a consensus target price of $30.00, indicating a potential upside of 293.18%. Given Kyntra Bio's stronger consensus rating and higher probable upside, analysts plainly believe Kyntra Bio is more favorable than Aardvark Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Kyntra Bio has a net margin of 2,199.13% compared to Aardvark Therapeutics' net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-61.71%	-56.29%
Kyntra Bio	2,199.13%	N/A	-36.71%

Summary

Kyntra Bio beats Aardvark Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Kyntra Bio compare to Oncolytics Biotech?

Oncolytics Biotech (NASDAQ:ONCY) and Kyntra Bio (NASDAQ:KYNB) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

In the previous week, Kyntra Bio had 1 more articles in the media than Oncolytics Biotech. MarketBeat recorded 1 mentions for Kyntra Bio and 0 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 0.00 equaled Kyntra Bio'saverage media sentiment score.

Company	Overall Sentiment
Oncolytics Biotech	Neutral
Kyntra Bio	Neutral

6.8% of Oncolytics Biotech shares are owned by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are owned by institutional investors. 0.1% of Oncolytics Biotech shares are owned by insiders. Comparatively, 4.2% of Kyntra Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Oncolytics Biotech has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Kyntra Bio has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

Oncolytics Biotech presently has a consensus price target of $8.50, suggesting a potential upside of 845.39%. Kyntra Bio has a consensus price target of $30.00, suggesting a potential upside of 293.18%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, equities analysts clearly believe Oncolytics Biotech is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Kyntra Bio has higher revenue and earnings than Oncolytics Biotech. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.31	N/A
Kyntra Bio	$6.44M	4.80	$183.45M	$40.46	0.19

Kyntra Bio has a net margin of 2,199.13% compared to Oncolytics Biotech's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-2,185.97%	-321.54%
Kyntra Bio	2,199.13%	N/A	-36.71%

Summary

Kyntra Bio beats Oncolytics Biotech on 10 of the 14 factors compared between the two stocks.

How does Kyntra Bio compare to Aldeyra Therapeutics?

Kyntra Bio (NASDAQ:KYNB) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

In the previous week, Kyntra Bio had 1 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 1 mentions for Kyntra Bio and 0 mentions for Aldeyra Therapeutics. Kyntra Bio's average media sentiment score of 0.00 equaled Aldeyra Therapeutics'average media sentiment score.

Company	Overall Sentiment
Kyntra Bio	Neutral
Aldeyra Therapeutics	Neutral

Kyntra Bio has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	4.80	$183.45M	$40.46	0.19
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A

72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by company insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Kyntra Bio presently has a consensus price target of $30.00, suggesting a potential upside of 293.18%. Aldeyra Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 142.29%. Given Kyntra Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Kyntra Bio is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Kyntra Bio has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market.

Kyntra Bio has a net margin of 2,199.13% compared to Aldeyra Therapeutics' net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-36.71%
Aldeyra Therapeutics	N/A	-57.34%	-36.33%

Summary

Kyntra Bio beats Aldeyra Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Kyntra Bio compare to Cue Biopharma?

Cue Biopharma (NASDAQ:CUE) and Kyntra Bio (NASDAQ:KYNB) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

Cue Biopharma has a beta of 2.45, indicating that its stock price is 145% more volatile than the broader market. Comparatively, Kyntra Bio has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are owned by institutional investors. 14.6% of Cue Biopharma shares are owned by company insiders. Comparatively, 4.2% of Kyntra Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Kyntra Bio has a net margin of 2,199.13% compared to Cue Biopharma's net margin of -59.65%. Kyntra Bio's return on equity of 0.00% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-59.65%	-98.30%	-53.69%
Kyntra Bio	2,199.13%	N/A	-36.71%

Kyntra Bio has lower revenue, but higher earnings than Cue Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$32.73M	3.63	-$26.60M	-$5.58	N/A
Kyntra Bio	$6.44M	4.80	$183.45M	$40.46	0.19

In the previous week, Kyntra Bio had 1 more articles in the media than Cue Biopharma. MarketBeat recorded 1 mentions for Kyntra Bio and 0 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 0.00 equaled Kyntra Bio'saverage media sentiment score.

Company	Overall Sentiment
Cue Biopharma	Neutral
Kyntra Bio	Neutral

Kyntra Bio has a consensus price target of $30.00, indicating a potential upside of 293.18%. Given Kyntra Bio's stronger consensus rating and higher probable upside, analysts plainly believe Kyntra Bio is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Kyntra Bio beats Cue Biopharma on 13 of the 16 factors compared between the two stocks.

Get Kyntra Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KYNB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KYNB vs. The Competition

Export

Metric	Kyntra Bio	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$30.89M	$791.45M	$5.20B	$12.48B
Dividend Yield	N/A	4.84%	16.11%	6.52%
P/E Ratio	0.19	1.66	23.91	24.70
Price / Sales	4.80	127.11	216.83	99.42
Price / Cash	N/A	20.06	35.06	57.09
Price / Book	-1.82	8.17	13.25	6.46
Net Income	$183.45M	-$3.71M	$113.80M	$337.01M
7 Day Performance	4.16%	2.59%	0.93%	1.69%
1 Month Performance	13.71%	4.41%	1.08%	3.81%
1 Year Performance	N/A	49.43%	10.03%	23.90%

Kyntra Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KYNB Kyntra Bio	3.6732 of 5 stars	$7.63 flat	$30.00 +293.2%	N/A	$30.89M	$6.44M	0.19	570
FTLF FitLife Brands	4.5307 of 5 stars	$11.08 -7.1%	$21.50 +94.0%	-18.4%	$112.04M	$81.46M	18.34	20	Gap Down High Trading Volume
AARD Aardvark Therapeutics	3.9205 of 5 stars	$4.79 -5.3%	$19.70 +311.3%	-59.1%	$110.39M	N/A	N/A	18	Analyst Upgrade Gap Down High Trading Volume
ONCY Oncolytics Biotech	1.9499 of 5 stars	$0.95 +3.0%	$8.50 +796.8%	-0.2%	$109.84M	N/A	N/A	30	Gap Up
ALDX Aldeyra Therapeutics	3.1753 of 5 stars	$1.83 +1.7%	$5.50 +200.5%	-47.3%	$108.58M	N/A	N/A	10	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KYNB) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kyntra Bio (KYNB) Competitors

KYNB vs. FTLF, AARD, ONCY, ALDX, and CUE

How does Kyntra Bio compare to FitLife Brands?

Summary

How does Kyntra Bio compare to Aardvark Therapeutics?

Summary

How does Kyntra Bio compare to Oncolytics Biotech?

Summary

How does Kyntra Bio compare to Aldeyra Therapeutics?

Summary

How does Kyntra Bio compare to Cue Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYNB vs. The Competition

Kyntra Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kyntra Bio (KYNB) Competitors

KYNB vs. FTLF, AARD, ONCY, ALDX, and CUE

How does Kyntra Bio compare to FitLife Brands?

Is FTLF or KYNB more profitable?

Do analysts prefer FTLF or KYNB?

Does the media prefer FTLF or KYNB?

Which has higher earnings & valuation, FTLF or KYNB?

Which has more risk & volatility, FTLF or KYNB?

Do institutionals & insiders have more ownership in FTLF or KYNB?

Summary

How does Kyntra Bio compare to Aardvark Therapeutics?

Do insiders & institutionals have more ownership in AARD or KYNB?

Which has stronger valuation & earnings, AARD or KYNB?

Does the media refer more to AARD or KYNB?

Which has more volatility & risk, AARD or KYNB?

Do analysts prefer AARD or KYNB?

Is AARD or KYNB more profitable?

Summary

How does Kyntra Bio compare to Oncolytics Biotech?

Does the media favor ONCY or KYNB?

Do insiders & institutionals hold more shares of ONCY or KYNB?

Which has more risk & volatility, ONCY or KYNB?

Do analysts rate ONCY or KYNB?

Which has higher earnings & valuation, ONCY or KYNB?

Is ONCY or KYNB more profitable?

Summary

How does Kyntra Bio compare to Aldeyra Therapeutics?

Does the media refer more to KYNB or ALDX?

Which has higher valuation & earnings, KYNB or ALDX?

Do insiders & institutionals hold more shares of KYNB or ALDX?

Do analysts recommend KYNB or ALDX?

Which has more risk & volatility, KYNB or ALDX?

Is KYNB or ALDX more profitable?

Summary

How does Kyntra Bio compare to Cue Biopharma?

Which has more risk and volatility, CUE or KYNB?

Do insiders & institutionals have more ownership in CUE or KYNB?

Is CUE or KYNB more profitable?

Which has preferable earnings & valuation, CUE or KYNB?

Does the media favor CUE or KYNB?

Do analysts rate CUE or KYNB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYNB vs. The Competition

Kyntra Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools